Evidence map›Paper›PMID 35015039›Full record

ArticleJAMA2022

Discriminative Accuracy of Chronic Obstructive Pulmonary Disease Screening Instruments in 3 Low- and Middle-Income Country Settings.

Trishul Siddharthan, Suzanne L Pollard, Shumonta A Quaderi, Natalie A Rykiel, Adaeze C Wosu, Patricia Alupo, Julie A Barber, Maria Kathia Cárdenas, Ram K Chandyo, Oscar Flores-Flores and 11 more

Open access · bronzeAbstract read
In one paragraph

Article in JAMA, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
48citing papers in PubMed, 2 pooled it
9.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

48 citing papers in PubMed, 2 syntheses or guidelines pooled it, 64 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

21 authors at 8 institutions in 5 countries.

Trishul SiddharthanDivision of Pulmonary and Critical Care, Miller School of Medicine, University of Miami, Miami, Florida.
Suzanne L PollardCenter for Global Non-Communicable Disease Research and Training, School of Medicine, Johns Hopkins University, Baltimore, Maryland.
Shumonta A QuaderiUCL Respiratory, University College London, London, United Kingdom.
Natalie A RykielCenter for Global Non-Communicable Disease Research and Training, School of Medicine, Johns Hopkins University, Baltimore, Maryland.
Adaeze C WosuCenter for Global Non-Communicable Disease Research and Training, School of Medicine, Johns Hopkins University, Baltimore, Maryland.
Patricia AlupoMakerere Lung Institute, Makerere University, Kampala, Uganda.
Julie A BarberDepartment of Statistical Science, University College London, London, United Kingdom.
Maria Kathia CárdenasCRONICAS Centre of Excellence in Chronic Diseases, Universidad Peruana Cayetano Heredia, Lima, Peru.
Ram K ChandyoDepartment of Community Medicine, Kathmandu Medical College, Nepal.
Oscar Flores-FloresCenter for Global Non-Communicable Disease Research and Training, School of Medicine, Johns Hopkins University, Baltimore, Maryland.
Bruce KirengaMakerere Lung Institute, Makerere University, Kampala, Uganda.
J Jaime MirandaCRONICAS Centre of Excellence in Chronic Diseases, Universidad Peruana Cayetano Heredia, Lima, Peru.
Sakshi MohanCentre for Health Economics, University of York, York, United Kingdom.
Federico RicciardiDepartment of Statistical Science, University College London, London, United Kingdom.
Arun K SharmaChild Health Research Project, Institute of Medicine Tribhuvan University, Kathmandu, Nepal.
Santa Kumar DasChild Health Research Project, Institute of Medicine Tribhuvan University, Kathmandu, Nepal.
Laxman ShresthaChild Health Research Project, Institute of Medicine Tribhuvan University, Kathmandu, Nepal.
Marta O SoaresCentre for Health Economics, University of York, York, United Kingdom.
William CheckleyCenter for Global Non-Communicable Disease Research and Training, School of Medicine, Johns Hopkins University, Baltimore, Maryland.
John R HurstUCL Respiratory, University College London, London, United Kingdom.
GECo Study Investigators
Johns Hopkins University · USUniversity College London · GBTribhuvan University · NPMakerere University · UGUniversidad Peruana Cayetano Heredia · PEUniversity of York · GBKathmandu Medical College Teaching Hospital · NPNational Institutes of Health · US

Funding

UJMT – ORWH – Gazzetta, Issa-BoubeD43TW009340 · FIC · UNIV OF NORTH CAROLINA CHAPEL HILL · PI William Checkley, Benjamin H. Chi · 2017 to 2026
$14.8M
Research training in chronic, non-communicable respiratory diseases in PeruD43TW011502 · FIC · JOHNS HOPKINS UNIVERSITY · PI CHECKLEY, WILLIAM, HARTINGER, STELLA MARIA · 2019 to 2023
$1.2M
Effectiveness of Low-dose Theophylline for the Management of Biomass-associated COPD in PeruK23HL146946 · NHLBI · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI SIDDHARTHAN, TRISHUL · 2019 to 2023
$985k
A community intervention to promote evidence-based mental health care for olderadults with depressive and anxiety symptoms.K43TW011586 · FIC · UNIVERSIDAD DE SAN MARTIN DE PORRES · PI FLORES-FLORES, OSCAR GUILLERMO · 2021 to 2025
$544k
FIC NIH HHS D43 TW009340FIC NIH HHS D43 TW011502FIC NIH HHS K43 TW011586Medical Research Council MR/P008984/1NHLBI NIH HHS K23 HL146946
6 · The paper itself

Abstract

Importance: Most of the global morbidity and mortality in chronic obstructive pulmonary disease (COPD) occurs in low- and middle-income countries (LMICs), with significant economic effects. Objective: To assess the discriminative accuracy of 3 instruments using questionnaires and peak expiratory flow (PEF) to screen for COPD in 3 LMIC settings. Design, Setting, and Participants: A cross-sectional analysis of discriminative accuracy, conducted between January 2018 and March 2020 in semiurban Bhaktapur, Nepal; urban Lima, Peru; and rural Nakaseke, Uganda, using a random age- and sex-stratified sample of the population 40 years or older. Exposures: Three screening tools, the COPD Assessment in Primary Care to Identify Undiagnosed Respiratory Disease and Exacerbation Risk (CAPTURE; range, 0-6; high risk indicated by a score of 5 or more or score 2-5 with low PEF [<250 L/min for females and <350 L/min for males]), the COPD in LMICs Assessment questionnaire (COLA-6; range, 0-5; high risk indicated by a score of 4 or more), and the Lung Function Questionnaire (LFQ; range, 0-25; high risk indicated by a score of 18 or less) were assessed against a reference standard diagnosis of COPD using quality-assured postbronchodilator spirometry. CAPTURE and COLA-6 include a measure of PEF. Main Outcomes and Measures: The primary outcome was discriminative accuracy of the tools in identifying COPD as measured by area under receiver operating characteristic curves (AUCs) with 95% CIs. Secondary outcomes included sensitivity, specificity, positive predictive value, and negative predictive value. Results: Among 10 709 adults who consented to participate in the study (mean age, 56.3 years (SD, 11.7); 50% female), 35% had ever smoked, and 30% were currently exposed to biomass smoke. The unweighted prevalence of COPD at the 3 sites was 18.2% (642/3534 participants) in Nepal, 2.7% (97/3550) in Peru, and 7.4% (264/3580) in Uganda. Among 1000 COPD cases, 49.3% had clinically important disease (Global Initiative for Chronic Obstructive Lung Disease classification B-D), 16.4% had severe or very severe airflow obstruction (forced expiratory volume in 1 second <50% predicted), and 95.3% of cases were previously undiagnosed. The AUC for the screening instruments ranged from 0.717 (95% CI, 0.677-0.774) for LFQ in Peru to 0.791 (95% CI, 0.770-0.809) for COLA-6 in Nepal. The sensitivity ranged from 34.8% (95% CI, 25.3%-45.2%) for COLA-6 in Nepal to 64.2% (95% CI, 60.3%-67.9%) for CAPTURE in Nepal. The mean time to administer the instruments was 7.6 minutes (SD 1.11), and data completeness was 99.5%. Conclusions and Relevance: This study demonstrated that screening instruments for COPD were feasible to administer in 3 low- and middle-income settings. Further research is needed to assess instrument performance in other low- and middle-income settings and to determine whether implementation is associated with improved clinical outcomes.

Indexed as

Developing CountriesPeak Expiratory Flow RateSurveys and QuestionnairesAdultAirway ObstructionCross-Sectional StudiesFeasibility StudiesFemaleForced Expiratory VolumeHumansMaleMiddle AgedNepalPeruPredictive Value of TestsPrevalenceTobacco Smoke Pollution

Identifiers

PMID35015039
PMCPMC8753498
OpenAlexW4205701164

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.